Metformin Compounding Legal Status: What Patients and Prescribers Need to Know

When Was Metformin FDA Approved and What Is Its Regulatory History?

Metformin hydrochloride received FDA approval on December 29, 1994, under NDA 020357, for Bristol-Myers Squibb's Glucophage brand. Generic versions flooded the market after patent expiration, and today dozens of approved generic manufacturers supply metformin immediate-release (IR) and extended-release (ER) tablets at low cost. The drug's regulatory history spans more than three decades of post-market surveillance, voluntary recalls, and label updates.

The DESI Era and Pre-1994 Use

Before the 1994 NDA approval, metformin was used widely in Europe and Canada. The FDA's Drug Efficacy Study Implementation (DESI) review process, which evaluated pre-1962 drugs, did not apply to metformin because it was never marketed in the United States before 1962. The 1994 approval came from a full New Drug Application process with modern clinical trial data, making metformin's FDA status cleaner than older biguanides such as phenformin, which was withdrawn in 1977 due to fatal lactic acidosis rates far exceeding those seen with metformin. [1]

UKPDS 34 and the Evidence Base That Cemented FDA Confidence

The United Kingdom Prospective Diabetes Study 34 (UKPDS 34, published in The Lancet in 1998) enrolled 1,704 overweight patients with newly diagnosed type 2 diabetes. Metformin reduced the risk of any diabetes-related endpoint by 32% (P<0.0023), all-cause mortality by 36% (P<0.011), and myocardial infarction by 39% (P<0.010) compared with conventional dietary therapy. [2] These results did not generate metformin's original approval, since that occurred four years earlier, but they substantially reinforced the FDA's confidence in the drug's benefit-risk profile and supported subsequent label expansions.

Label Expansions After 1994

The FDA has approved several label supplements since 1994. Extended-release metformin (Glucophage XR) received approval in October 2000. Pediatric labeling was expanded to include patients aged 10 years and older. Combination products pairing metformin with glipizide, glyburide, sitagliptin, saxagliptin, and other agents each carry their own NDA numbers. All approved formulations appear in the FDA's Drugs@FDA database, which is the authoritative public record. [3]

What Does the Metformin FDA Label Say?

The current prescribing information for metformin hydrochloride tablets, maintained in the FDA's Drugs@FDA database, covers indications, contraindications, warnings, dosing, and a boxed warning. Prescribers and compounding pharmacies both reference the approved labeling when making clinical and legal decisions.

Boxed Warning: Lactic Acidosis

All metformin products carry a black-box warning for lactic acidosis. The label states that lactic acidosis is a rare but serious metabolic complication that can occur due to metformin accumulation. The estimated incidence is approximately 0.03 cases per 1,000 patient-years. [4] Risk factors include renal impairment, hepatic impairment, congestive heart failure, and excessive alcohol use. The label warns prescribers to withhold metformin before iodinated contrast procedures in patients with eGFR <60 mL/min/1.73 m² and to reassess renal function 48 hours after the procedure.

The FDA label explicitly states: "Metformin is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²." [4] This contraindication reflects a 2016 label update in which the FDA replaced the older serum creatinine threshold language with the eGFR-based cutoff, extending access to some patients with mild-to-moderate chronic kidney disease who had previously been excluded by the older, more conservative serum creatinine criteria.

Dosing, Formulations, and Renal Thresholds

Standard IR dosing starts at 500 mg twice daily or 850 mg once daily with meals, titrated over several weeks to a maximum of 2,550 mg per day. Extended-release tablets are taken once daily with the evening meal, with a maximum of 2,000 mg per day (or 2,500 mg for some ER formulations). The label specifies eGFR monitoring at baseline and periodically during treatment, with dose reduction or discontinuation recommended when eGFR falls between 30 and 45 mL/min/1.73 m². [4]

NDMA and the 2020-2022 Recalls

Beginning in May 2020, the FDA announced that some extended-release metformin products contained N-nitrosodimethylamine (NDMA) above the acceptable daily intake limit of 96 nanograms per day. Multiple manufacturers, including Apotex, Amneal, Bayshore, and others, issued voluntary recalls between 2020 and 2022. [5] The FDA tested both the recalled lots and the remaining marketed products. No recalls were issued for immediate-release metformin formulations. As of early 2025, the FDA has not identified any currently marketed metformin products with NDMA above its interim limit, and no active drug shortage exists as a result of those recalls. [5]

What Is the Legal Status of Compounded Metformin?

Compounded metformin occupies a legally restricted space. Because metformin is commercially available at low cost in FDA-approved formulations, the legal justification for compounding is narrow. Understanding that space requires knowing how federal pharmacy compounding law works under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Quality and Security Act of 2013. [6]

How 503A Compounding Pharmacies May Dispense Metformin

A 503A pharmacy is a traditional compounding pharmacy that prepares medications for individual patients based on a valid prescription from a licensed practitioner. Under 503A, a compounded drug is exempt from FDA's new drug approval requirements if it meets several criteria. [6] Those criteria include:

• The drug is compounded for an identified individual patient with a valid prescription.
• The drug is not essentially a copy of a commercially available drug.
• The drug is not on FDA's list of drugs that may not be compounded (the "withdrawn or removed from the market for safety reasons" list).
• The compounding complies with USP standards.

Metformin is not on the FDA's list of drugs withdrawn or removed for safety reasons, so that restriction does not apply. The "essentially a copy" provision is the critical one. A 503A pharmacy compounding a standard 500 mg metformin IR tablet is almost certainly producing an essentially a copy of a commercially available product, which removes the 503A exemption and subjects the compounder to FDA enforcement discretion. [6]

The legal window remains open if the prescribing clinician can document a clinical difference: a patient who cannot swallow solid tablets may need a liquid suspension; a patient with a documented allergy to an excipient present in all commercial formulations may need an excipient-free preparation; or a patient may require a dose strength not commercially available. In those narrow scenarios, a 503A pharmacy can compound metformin with legal justification, provided it meets USP compounding standards.

Why 503B Outsourcing Facilities Cannot Routinely Produce Metformin

503B outsourcing facilities are permitted to compound large batches without patient-specific prescriptions and to sell those batches to healthcare facilities for office use. In exchange, they must register with the FDA, comply with current Good Manufacturing Practice (cGMP), and limit compounding to drugs that appear on either the FDA's 503B Bulks List or the FDA's drug shortage list. [6]

Metformin does not appear on the FDA's 503B Bulks List, the list of bulk drug substances that may be used to compound drugs under Section 503B. [7] The FDA's process for adding a drug to that list requires evidence that the compounded version provides clinical differences not achievable with the approved product. Metformin's generic availability at pennies per tablet makes a compelling clinical-difference argument extremely difficult to construct.

A 503B facility could legally compound metformin only if the FDA added it to an active drug shortage list. No such shortage existed as of early 2025.

The Difference Between a Shortage and a Market Gap

A common misconception in the GLP-1 and metabolic-health telehealth space is that limited insurance coverage or high out-of-pocket costs for branded products constitutes a "shortage" that permits compounding. It does not. The FDA defines a drug shortage as a situation in which the total supply of all clinically interchangeable versions of an FDA-regulated drug is inadequate to meet the current or projected demand at the patient level. [8] Price and coverage are not components of the FDA's shortage definition. Generic metformin is manufactured by dozens of facilities worldwide, and a shortage designation is not plausible under current supply conditions.

The HealthRX clinical compliance team uses the following four-question framework when evaluating whether a compounding order for any FDA-approved small-molecule drug is legally defensible. Each question must be answered "yes" before a prescription is sent to a compounding pharmacy:

1. Is there a documented patient-specific medical need that cannot be met by an FDA-approved product (allergy, dysphagia, intolerable excipient)?
2. Is the pharmacy a licensed 503A compounder for patient-specific prescriptions, or is there an active FDA shortage if using a 503B facility?
3. Is the drug absent from FDA's list of drugs withdrawn or removed for safety reasons?
4. Does the compounded preparation differ meaningfully from any commercially available dosage form in route, strength, or base formulation?

For metformin, questions 1 and 4 are the only ones likely to generate a "yes" in clinical practice, and both require documented patient-specific justification in the chart.

Metformin Safety: Post-Market Surveillance and the FDA Sentinel System

Metformin's safety profile is one of the best-characterized of any oral antihyperglycemic agent. Decades of post-market surveillance, including data from the FDA's Sentinel System, have confirmed a favorable risk-benefit ratio for the approved patient population.

FDA Sentinel System Findings

The FDA Sentinel System is an active pharmacovigilance network that accesses the de-identified electronic health records and insurance claims of more than 100 million Americans. [9] Sentinel analyses on metformin have examined cardiovascular outcomes, lactic acidosis incidence, and renal safety. A 2014 FDA safety communication updated the labeling to allow use in patients with eGFR as low as 45 mL/min/1.73 m², citing Sentinel and other database analyses showing that the risk of lactic acidosis was not meaningfully elevated at that eGFR threshold compared with patients with normal renal function. [9]

The American Diabetes Association (ADA) 2024 Standards of Care in Diabetes endorsed metformin as a first-line pharmacologic therapy for type 2 diabetes, noting: "Metformin remains the preferred initial pharmacologic agent for the treatment of type 2 diabetes, given its efficacy, safety, tolerability, and low cost." [10]

Gastrointestinal Tolerability and Extended-Release Formulations

Gastrointestinal side effects, primarily nausea, diarrhea, and abdominal cramping, affect 20-30% of patients initiating metformin IR, with rates declining after the first few weeks of use. Extended-release formulations reduce GI adverse event rates. A randomized comparison published in Diabetes Care found that ER formulations produced significantly fewer GI complaints than IR at equivalent doses, which contributed to their regulatory approval and their practical role in improving adherence. [11]

Vitamin B12 Depletion: An Underappreciated Risk

Long-term metformin use reduces vitamin B12 absorption by interfering with calcium-dependent membrane action in the terminal ileum. The UKPDS follow-up data and a subsequent trial published in the British Medical Journal demonstrated that approximately 5.8% of metformin users develop biochemically significant B12 deficiency after 4 years of use, compared with 2.4% of placebo users (P<0.001 in the BMJ trial). [12] The current FDA label recommends periodic monitoring of hematologic parameters and B12 levels in patients on long-term metformin. Patients on metformin for more than 4 years should have serum B12 checked at minimum every 2 years.

NDMA: What Patients Should Know About the 2020 Recalls

NDMA is a probable human carcinogen classified by the International Agency for Research on Cancer in Group 2A. [13] Its detection in ER metformin products above the FDA interim acceptable daily intake limit of 96 nanograms prompted significant patient anxiety and pharmacy-level shortages of ER formulations in 2020-2021. The FDA's investigation found that NDMA formed during the manufacturing or storage of ER tablets, not during the manufacture of IR tablets. Patients on IR metformin were not affected. The FDA advises patients who received a recalled lot to continue their medication until they can speak with their prescriber, because abrupt discontinuation of metformin poses a risk of blood glucose decompensation that may exceed any incremental NDMA risk from a limited period of continued use. [5]

Metformin in Off-Label and Emerging Clinical Contexts

Beyond type 2 diabetes, metformin is used off-label in polycystic ovary syndrome (PCOS), prediabetes, and as a potential longevity intervention. These off-label uses generate prescribing volume and, in some cases, patient requests for compounded formulations.

PCOS and Polycystic Ovary Syndrome

The American Society for Reproductive Medicine (ASRM) practice committee opinion on PCOS acknowledges metformin as a treatment option for menstrual irregularity and ovulation induction in PCOS patients who do not respond to lifestyle modification. [14] Because standard commercial metformin IR and ER tablets cover the doses used in PCOS (typically 1,500-2,000 mg per day), there is no regulatory basis for compounding metformin for PCOS on the grounds of a unique dosing need.

Prediabetes and the Diabetes Prevention Program

The ADA recommends considering metformin 850 mg twice daily for patients with prediabetes, particularly those under age 60 with BMI >35, prior gestational diabetes, or rising HbA1c despite lifestyle intervention. [10] The Diabetes Prevention Program Outcomes Study (DPPOS) showed that metformin use was associated with a 17% reduction in diabetes incidence at 15-year follow-up compared with placebo. [15] Again, these doses fall within the commercially available range, and no compounding justification exists on clinical grounds alone.

Longevity Research and TAME

The Targeting Aging with Metformin (TAME) trial, a multicenter, randomized, placebo-controlled trial sponsored by the American Federation for Aging Research and funded in part by the NIH, is currently enrolling approximately 3,000 adults aged 65-79 without diabetes to test whether metformin 1,500 mg per day delays the onset of aging-related diseases. [16] TAME uses commercially sourced metformin tablets supplied under an FDA Investigational New Drug (IND) exemption. The existence of TAME does not create a compounding pathway for longevity-indication metformin outside of the trial.

Regulatory Compliance Checklist for Telehealth Prescribers

Telehealth clinicians prescribing metformin should confirm the following before issuing a prescription, whether for a commercial pharmacy or a compounding pharmacy:

• eGFR documented within the past 12 months (or within 48 hours before initiation in higher-risk patients).
• Baseline HbA1c and fasting plasma glucose recorded.
• Allergy and excipient intolerance history documented if sending to a 503A compounder.
• Clinical indication for compounding (non-standard dose, liquid formulation, allergy) stated explicitly in the chart note.
• Pharmacy verified as licensed in the patient's state and registered with the FDA if a 503B outsourcing facility.
• Patient counseled on GI side effects, B12 monitoring schedule, and signs of lactic acidosis.

The FDA's Drugs@FDA database and the FDA's drug shortage database are both publicly accessible and should be checked before any clinical assertion that a compounded version of metformin is legally required. [3][8]